Design Therapeutics, Inc. (DSGN) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing GeneTAC® molecules, a novel class of small-molecule gene-targeted chimeras designed to treat diseases caused by inherited nucleotide repeat expansion mutations. The company has no approved products and has not generated any revenue from product sales.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(20.2) million | $(19.1) million | $(37.8) million | $(36.8) million |
| Net Loss Per Share | $(0.32) | $(0.34) | $(0.61) | $(0.65) |
| Operating Expenses | $22.2 million | $21.6 million | $41.9 million | $42.0 million |
| Cash & Investments | $207.4 million (as of June 30, 2026) | |||
| Accumulated Deficit | $334.8 million (as of June 30, 2026) | |||
| Net Cash Used in Operating Activities | N/A | $(32.0) million | $(31.2) million |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased slightly by $0.6 million in Q2 2026 compared to Q2 2025, driven by increased Friedreich ataxia (FA) clinical activities and higher indirect personnel costs. For the six-month period, expenses decreased marginally by $0.1 million.
- Research & Development (R&D): R&D expenses rose to $16.4 million in Q2 2026 from $15.7 million in Q2 2025. This increase was primarily due to the initiation of clinical development for the myotonic dystrophy type-1 (DM1) program (DT-818), which was previously categorized under "Other direct" expenses.
- Liquidity: Cash, cash equivalents, and investment securities decreased by $12.4 million from December 31, 2025, to June 30, 2026, primarily due to operating cash burn partially offset by financing activities.
- Financing Activity: During the six months ended June 30, 2026, the company raised approximately $19.9 million in net proceeds through its At-The-Market (ATM) offering program, selling 2,006,550 shares. No ATM sales occurred in Q2 2026 specifically.
Guidance, Outlook, and Clinical Updates
- Lead Program (FA - DT-216P2): In May 2026, the company announced positive biomarker and clinical data from the four-week IV cohorts of the RESTORE-FA Phase 1/2 trial. Results showed dose-dependent increases in frataxin (FXN) levels and improvements in clinical measures (mFARS, upright stability, fatigue). The company plans to modify the trial to evaluate a 1 mpk dose in a 12-week cohort and expects to provide an update on registrational plans in Q4 2026, with 12-week data expected in Q1 2027.
- FECD Program (DT-168): A Phase 2 biomarker trial is ongoing. Data readout is now expected in 2027 due to a delay in the supply of blow-fill-seal eye droppers.
- DM1 Program (DT-818): Dosing of patients in a Phase 1 multiple-ascending dose (MAD) trial was initiated in the first half of 2026. Data is anticipated in 2027.
- Liquidity Outlook: Management believes existing cash and investment resources ($207.4 million) are sufficient to fund operations for more than 12 months following the filing date. However, the company expects to incur significant losses for the foreseeable future and will require substantial additional capital to complete development and commercialization.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing, reliance on third-party manufacturers, and potential regulatory delays. The company previously faced a clinical hold on DT-216P2 in June 2025, which was lifted in December 2025.
Investor Verification Checklist
- Verify the timeline for the RESTORE-FA 12-week data readout (expected Q1 2027) and the Q4 2026 registrational plan update.
- Confirm the status of the supply chain delay for DT-168 eye droppers and its impact on the 2027 data readout.
- Monitor the company's cash burn rate relative to the $207.4 million cash balance to assess the runway for future capital raises.
- Review the terms of the ATM program, noting $53.9 million remains available for future issuances as of June 30, 2026.
- Assess the impact of the new DM1 clinical program on future R&D expense projections.